The translocation of vimentin to the nuclei up on trabectedin treatment suggests that the tumors under treatment could select highly aggressive cells in keeping with previous reports in nasopharyngeal carcinoma where the nuclear vimentin expression correlates with lower survival [41]. The gene discussed is VIM; the disease is nasopharyngeal carcinoma.